Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes

Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes

Vivian T Thieu,1 Susan Robinson,2 Tessa Kennedy-Martin,2 Kristina S Boye,1 Luis-Emilio Garcia-Perez1 1Global Patient Outcomes and Real-World Evidence, Eli Lilly and Company, Indianapolis, IN, USA; 2Kennedy-Martin Health Outcomes (KMHO), Brighton, UK Purpose: The importance of patient-centered care...

Full description

Bibliographic Details
Main Authors: Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE
Format: Article
Language:English
Published: Dove Medical Press 2019-04-01
Series:Patient Preference and Adherence
Subjects:
T2D mellitus
discrete choice experiment
GLP-1 RA
insulin
Online Access:https://www.dovepress.com/patient-preferences-for-glucagon-like-peptide-1-receptor-agonist-treat-peer-reviewed-article-PPA

Internet

https://www.dovepress.com/patient-preferences-for-glucagon-like-peptide-1-receptor-agonist-treat-peer-reviewed-article-PPA

Similar Items